Latest news with #CMV
Business Upturn
06-08-2025
- Business
- Business Upturn
Global Renal Transplant Therapeutics Market is Expected to Cross ~USD 18 Billion by 2032
New York, USA, Aug. 06, 2025 (GLOBE NEWSWIRE) — Global Renal Transplant Therapeutics Market is Expected to Cross ~USD 18 Billion by 2032 | DelveInsight The demand for renal transplant therapeutics is increasing due to several important factors. Chief among these is the global rise in kidney transplant procedures, driven by the growing incidence of chronic kidney disease, renal failure, and end-stage renal disease (ESRD), all of which can cause irreversible kidney damage and necessitate transplantation. Furthermore, ongoing advancements in research and development, along with the launch of innovative therapies designed to prevent transplant rejection, are also playing a vital role in propelling market growth. DelveInsight's Renal Transplant Therapeutics Market Insights report provides the current and forecast market analysis, individual leading renal transplant therapeutics companies' market shares, challenges, renal transplant therapeutics market drivers, barriers, trends, and key market renal transplant therapeutics companies in the market. Key Takeaways from the Renal Transplant Therapeutics Market Report As per DelveInsight estimates, North America is anticipated to dominate the global renal transplant therapeutics market during the forecast period. In the drug class segment of the renal transplant therapeutics market, the calcineurin inhibitors category accounted for the largest market share in 2024. Notable renal transplant therapeutics companies such as Novartis AG, Sanofi, Astellas Pharma Inc., Asahi Kasei Corporation, F. Hoffmann-La Roche Ltd., Pfizer Inc., Bristol-Myers Squibb Company, GSK plc, Biogen, Zydus Group, Eledon Pharmaceuticals, Inc., AbbVie Inc., CSL, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., and several others are currently operating in the renal transplant therapeutics market. and several others are currently operating in the renal transplant therapeutics market. In March 2025, Zydus announced the launch of ANVIMO (Letermovir), marking a significant advancement in the prevention of Cytomegalovirus (CMV) infection among kidney transplant recipients. ANVIMO offers a safer, well-tolerated, and effective alternative to existing therapies, with superior safety, fewer side effects, and the potential to enhance post-transplant outcomes, making it a valuable addition to renal transplant care. announced the launch of ANVIMO (Letermovir), marking a significant advancement in the prevention of Cytomegalovirus (CMV) infection among kidney transplant recipients. ANVIMO offers a safer, well-tolerated, and effective alternative to existing therapies, with superior safety, fewer side effects, and the potential to enhance post-transplant outcomes, making it a valuable addition to renal transplant care. In March 2025, Hansa Biopharma AB announced the completion of enrollment for its 20-HMedIdeS-19 Post Authorization Efficacy and Safety (PAES) study, an open-label, Phase 3 confirmatory trial in Europe. The study is evaluating one-year patient and graft survival in highly sensitized patients who have undergone HLA-incompatible kidney transplantation following desensitization treatment with imlifidase, aiming to further validate the therapy's clinical effectiveness and safety. announced the completion of enrollment for its 20-HMedIdeS-19 Post Authorization Efficacy and Safety (PAES) study, an open-label, Phase 3 confirmatory trial in Europe. The study is evaluating one-year patient and graft survival in highly sensitized patients who have undergone HLA-incompatible kidney transplantation following desensitization treatment with imlifidase, aiming to further validate the therapy's clinical effectiveness and safety. In February 2025, Eledon Pharmaceuticals, Inc. announced that its investigational anti-CD40L antibody, tegoprubart, was utilized as a key component of the immunosuppressive regimen in a groundbreaking xenotransplantation procedure. On January 25, 2025, a patient received a genetically modified pig kidney at Massachusetts General Hospital (MGH), with the transplant performed in collaboration with eGenesis, marking a significant milestone in the advancement of cross-species organ transplantation. To read more about the latest highlights related to the renal transplant therapeutics market, get a snapshot of the key highlights entailed in the Global Renal Transplant Therapeutics Market Report Renal Transplant Therapeutics Overview Renal transplant therapeutics encompass a range of pharmacological strategies aimed at ensuring graft survival, minimizing rejection, and managing post-transplant complications. The cornerstone of therapy includes immunosuppressive agents such as calcineurin inhibitors, antiproliferative agents, and corticosteroids. These drugs work synergistically to suppress the immune system and prevent acute and chronic rejection of the transplanted kidney. Innovations in immunosuppressive regimens have significantly improved short-term graft survival rates, although long-term outcomes are still challenged by drug toxicity, infections, and the development of donor-specific antibodies. Emerging therapeutics are now targeting more precise immune pathways, such as co-stimulatory blockers and monoclonal antibodies, to offer more targeted immunosuppression with fewer side effects. Additionally, the field is exploring biomarkers for early detection of rejection and personalized dosing strategies using pharmacogenomics. Efforts are also underway to develop tolerance-inducing therapies that could potentially eliminate the need for lifelong immunosuppression. These advancements, along with supportive therapies to manage comorbidities like hypertension and infections, are shaping a more patient-centric and effective approach to renal transplant care. Renal Transplant Therapeutics Market Insights North America is anticipated to dominate the renal transplant therapeutics market, driven by multiple key factors. These include the increasing incidence of kidney disorders such as chronic kidney disease and end-stage renal disease (ESRD), a growing number of kidney transplant procedures, and a robust healthcare infrastructure. Additionally, major regional players are making significant strides in developing transplant-related therapies. For instance, in October 2024, Biogen announced that its investigational anti-CD38 monoclonal antibody, felzartamab, received Breakthrough Therapy Designation (BTD) from the U.S. FDA for the treatment of late antibody-mediated rejection (AMR) in kidney transplant patients, excluding cases with concurrent T-cell–mediated rejection. As a result, the synergistic effect of rising transplant volumes, high disease burden, and sustained therapeutic innovation is expected to drive substantial market growth in North America from 2025 to 2032. To know more about why North America is leading the market growth in the renal transplant therapeutics market, get a snapshot of the Renal Transplant Therapeutics Market Outlook Renal Transplant Therapeutics Market Dynamics The renal transplant therapeutics market is shaped by a combination of clinical advancements, increasing disease burden, and evolving healthcare infrastructure. The rising global prevalence of CKD and ESRD continues to drive demand for kidney transplantation as a preferred treatment modality. This, in turn, has amplified the need for effective immunosuppressive and anti-rejection therapies. Key therapeutic classes include calcineurin inhibitors, corticosteroids, antiproliferative agents, and newer biologics like monoclonal antibodies, which have significantly improved graft survival rates and reduced rejection episodes. One of the major dynamics influencing the market is the ongoing innovation in immunosuppressive regimens. The development of more selective and targeted therapies is aimed at minimizing long-term complications such as infections, malignancies, and nephrotoxicity, which are commonly associated with conventional immunosuppressants. Moreover, research into personalized medicine approaches, including genetic profiling to predict rejection risk, has opened new avenues for tailored treatment plans that enhance patient outcomes and long-term graft survival. The market is also impacted by the availability and accessibility of transplantation infrastructure, including organ donation systems, surgical facilities, and post-transplant care. High-income regions like North America and Western Europe dominate the market due to advanced healthcare systems, robust transplant programs, and favorable reimbursement policies. In contrast, emerging markets in Asia-Pacific and Latin America are showing growing potential, driven by increasing awareness, improving healthcare access, and government initiatives to strengthen organ donation and transplantation frameworks. Regulatory and policy frameworks play a critical role in shaping the renal transplant therapeutics landscape. Stringent regulations regarding drug approval, pricing, and post-marketing surveillance can both facilitate and hinder market growth. In addition, the presence of biosimilars and generic immunosuppressants has intensified competition, especially in cost-sensitive regions, providing more affordable options but also challenging the market share of originator brands. Lastly, challenges such as organ shortage, high treatment costs, and long-term medication adherence continue to hinder optimal market expansion. Despite these hurdles, the growing pipeline of novel immunomodulatory drugs, the rise of living donor programs, and advancements in transplant diagnostics and monitoring tools suggest a positive outlook for the renal transplant therapeutics market over the coming decade. Get a sneak peek at the renal transplant therapeutics market dynamics @ Renal Transplant Therapeutics Market Trends Report Metrics Details Coverage Global Study Period 2022–2032 Renal Transplant Therapeutics Market CAGR ~6% Renal Transplant Therapeutics Market Size by 2032 ~USD 18 Billion Key Renal Transplant Therapeutics Companies Novartis AG, Sanofi, Astellas Pharma Inc., Asahi Kasei Corporation, F. Hoffmann-La Roche Ltd., Pfizer Inc., Bristol-Myers Squibb Company, GSK plc, Biogen, Zydus Group, Eledon Pharmaceuticals, Inc., AbbVie Inc., CSL, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., and others Renal Transplant Therapeutics Market Assessment Renal Transplant Therapeutics Market Segmentation Renal Transplant Therapeutics Market Segmentation By Drug Class: Calcineurin Inhibitors, Interleukin Inhibitors, mTOR Inhibitors, IMPDH Inhibitors, and Others Renal Transplant Therapeutics Market Segmentation By Route of Administration: Oral and Parenteral Renal Transplant Therapeutics Market Segmentation By Modality: Small Molecule and Biologics Renal Transplant Therapeutics Market Segmentation By Geography : North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the renal transplant therapeutics market are set to emerge as the trendsetter explore @ Renal Transplant Therapeutics Analysis Table of Contents 1 Renal Transplant Therapeutics Market Report Introduction 2 Renal Transplant Therapeutics Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 Renal Transplant Therapeutics Market Key Factors Analysis 6 Renal Transplant Therapeutics Market Porter's Five Forces Analysis 7 Renal Transplant Therapeutics Market Layout 8 Renal Transplant Therapeutics Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us Interested in knowing the renal transplant therapeutics market by 2032? Click to get a snapshot of the Renal Transplant Therapeutics Market Analysis Related Reports Interleukin Inhibitors Market Interleukin Inhibitors Market Size, Target Population, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key interleukin inhibitors companies, including AbbVie, Sanofi, Regeneron, Johnson & Johnson, Novartis, among others. mTOR Inhibitors Market mTOR Inhibitors Market Size, Target Population, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key mTOR inhibitors companies, including Novartis, Pfizer, AstraZeneca, Merck, AbbVie, Bristol Myers Squibb, Hoffmann-La Roche, among others. Chronic Kidney Disease Market Chronic Kidney Disease Market Insight, Epidemiology and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key CKD companies, including ProKidney, Reata Pharmaceuticals, Inc., Novo Nordisk A/S, Boehringer Ingelheim, Eli Lilly and Company, KBP Biosciences, Kibow Pharma, Cincor Pharma, AstraZeneca, Allena Pharmaceuticals, DiaMedica Therapeutics Inc., Lexicon Pharmaceuticals, Sanofi, among others. Chronic Kidney Disease Pipeline Chronic Kidney Disease Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CKD companies, including AstraZeneca, Eli Lilly and Company, Shandong Suncadia Medicine, Boehringer Ingelheim, AdAlta, Alebund Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, Roche, MC2 Therapeutics, Allena Pharmaceuticals, Regulus Therapeutics, UnicoCell Biomed, Regeneron Pharmaceuticals, among others. End-Stage Renal Disease Market End-Stage Renal Disease Market Insight, Epidemiology and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key ESRD companies, including Medtronic PLC, B. Braun SE, Asahi Kasei Medical Co. Ltd, Cantel Medical (STERIS), Nikkiso Co. Ltd, Nipro Corporation, Fresenius SE & Co. KGaA, Baxter International Inc., Becton, Dickinson and Company, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
CTV News
29-07-2025
- Automotive
- CTV News
Transport forced off the road to avoid a head-on crash in northern Ont.
A commercial motor vehicle rolled over on Highway 64 in French River on Monday evening to avoid a crash with an oncoming vehicle. A commercial motor vehicle rolled over on Highway 64 in French River on Monday evening to avoid a crash with an oncoming vehicle. Police said the CMV had to swerve to avoid the crash with the passenger vehicle, which had crossed the centre lane. That driver fled the scene. Ontario Provincial Police closed the highway in both directions for more than six hours following the incident, which took place around 7:20 p.m. 'No injuries were reported when a CMV veered towards the right shoulder of the highway to prevent a head-on collision with a vehicle travelling over the centre line into oncoming traffic, causing the CMV to rollover,' police said in a news release Tuesday. 'The OPP is seeking the public's assistance in locating the vehicle that failed to remain and was described as a black Volkswagen Golf or possibly Jetta hatchback with two occupants.' Anyone with information regarding the incident is asked to call the Nipissing West OPP at 1-888-310-1122. To remain anonymous, call Crime Stoppers at 1-800-222-8477 (TIPS) or submit information online where you may be eligible to receive a cash reward of up to $2,000. Use Reference No. E251006747.
Business Wire
29-07-2025
- Business
- Business Wire
SpyBiotech Fortifies Board with Biotech Veteran Stuart Chaffee
OXFORD, England & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- SpyBiotech, a biotechnology company pioneering novel vaccine platform technologies, today announced the appointment of Stuart Chaffee, PhD, as an independent member of its Board of Directors. SpyBiotech announces the appointment of Stuart Chaffee, PhD, as an independent member of its Board of Directors Share Stuart Chaffee, currently Chief Executive Officer of QuantX Biosciences, brings over two decades of experience in the biotechnology and biopharma industry. He has played a pivotal role in the inception of four publicly traded biotechnology companies and has successfully raised over $900 million in private and public capital. In his previous operating role as Chief Business Officer at Affinivax, Inc., Chaffee was instrumental in driving the company's strategic growth, culminating in its acquisition by GSK for up to $3.3 billion. His expertise in business development and advising innovative biotech ventures positions him to provide invaluable strategic guidance as SpyBiotech advances its clinical pipeline and expands its proprietary SpyTag/SpyCatcher™ and other related protein superglue technology. SpyBiotech's platform leverages the SpyTag/SpyCatcher system—a protein superglue that enables rapid, efficient, and stable antigen binding to vaccine delivery platforms. This technology offers a plug-and-play approach to vaccine development, minimizing risks while enhancing immunogenicity. The company recently completed vaccinations in its Phase I trial for SPYVLP01, a vaccine candidate targeting cytomegalovirus (CMV), underscoring the critical momentum towards addressing a pathogen that leads to chronic developmental health consequences. "I am honored to join SpyBiotech's Board at such an exciting juncture in the company's journey," said Stuart Chaffee, PhD. "SpyBiotech's innovative SpyTag/SpyCatcher platform and commitment to developing transformative vaccines align closely with my passion for patient-centric innovation. I look forward to contributing my experience to accelerate the company's growth and bring these groundbreaking therapies to those who need them most." "Stuart's track record of building high-value biotech enterprises and navigating complex strategic landscapes makes him an outstanding addition to our Board," said Eddie Gray, Chairman of SpyBiotech. "His insights will be crucial as we propel our clinical programs forward and harness our unique technology to tackle some of the world's most pressing health challenges. We are thrilled to welcome him to the team." About SpyBiotech SpyBiotech is a clinical-stage biotechnology company with novel vaccine platform technologies that can target infectious diseases, cancer, and chronic diseases. The company was spun out of the University of Oxford in 2017 backed by Oxford Science Enterprises (OSE) and Google Ventures (GV). Based on science developed at the University of Oxford, SpyBiotech's novel vaccine platform is based on a proprietary protein 'superglue' technology, which binds antigens to vaccine delivery platforms in a way that minimizes delivery risk and enhances immunogenicity and efficacy. This makes it ideal for use against infectious diseases in challenging environments, such as in the developing world, but also with potential application in non-infectious disease settings such as cancer. SpyBiotech has the exclusive rights from the University of Oxford to apply, commercialize and sub-license the SpyTag/SpyCatcher and related technology in vaccine development.
The Citizen
28-07-2025
- Health
- The Citizen
Stem Cell Donor Needed for Young Lives at Risk
Registering is free and simple, and if you're between the ages of 17 and 55 and in good health, you could be the match these families are waiting for. DKMS Africa, a non-profit organisation committed to the fight against blood cancer and blood disorders, is appealing to potential donors to help save two young lives. Two-year-old Oyintando and 21-year-old Zachary are urgently searching for matching donors to survive. Two young lives on hold Following numerous hospital visits, Oyintando was initially diagnosed with Cytomegalovirus (CMV), which is a common and usually harmless virus that causes problems in babies and people with weakened immune systems. After six weeks of treatment, a follow-up referral led doctors to finally diagnose him with Wiskott-Aldrich Syndrome. This is a rare, life-changing genetic disorder that weakens the immune system and affects blood clotting. 'I was terrified when I heard the diagnosis,' says his mother, Bonakele, who had lost another child years earlier to similar symptoms. 'The doctors explained everything to me, and over time, I had to come to terms with the reality.' ALSO READ: Baby girl's life saved by surgery 21-year-old Zachary, a third-year student at Nelson Mandela University, had his life change overnight in February 2025. He went on a routine visit to check on low blood pressure but ended up leaving with an Aplastic Anaemia diagnosis. This is a condition where the bone marrow fails to produce enough new blood cells. He now relies on weekly transfusions and has undergone multiple rounds of medication. Unfortunately, none of his family members are suitable donors. You Could Be the Match 'Both Oyintando and Zachary urgently need stem cell transplants, and their survival depends on the generosity of others,' says Palesa Mokomele, head of Community Engagement and Communications at DKMS Africa Ways to help Members of the public can learn more and register as potential donors at The process is free, simple, and non-invasive, and one registration could mean the difference between life and death for patients like Oyintando and Zachary. In different corners of South Africa, two families are holding onto hope, united by a desperate need for a stem cell donor who could give their loved ones a second chance at life.
CTV News
16-07-2025
- Automotive
- CTV News
Safety check leads to charges for driver, company along Highway 400 in Barrie
A commercial motor vehicle was stopped by officers of the Ontario Provincial Police Highway Safety Division in Barrie for an insecure load on Highway 400. (OPP/X) A commercial motor vehicle (CMV) traveling along Highway 400 was stopped by officers of the Ontario Provincial Police Highway Safety Division for an insecure load. The incident occurred on Wednesday evening in Barrie, when police noticed the truck travelling with insufficient tie-downs. In the photo posted by OPP, the CMV appears to be carrying a large quantity of interlock. After inspection, police determined that the load posed a safety risk to other drivers along the highway due to inadequate restraint measures. Officers say both the driver and the company were charged. OPP confirmed that necessary load security devices were installed on-site before the truck could continue its route. The OPP took it to X to emphasize the importance of proper load securing as part of its ongoing commitment to road safety.
